Vision Fund sold 4.9 million shares in cancer test developer Guardant Health at more than four times their price in the company's 2018 IPO.
Telecommunications and internet group SoftBank’s Vision Fund has sold approximately $377m of shares in US-based, publicly-listed oncology diagnostics technology developer Guardant Health, Bloomberg reported yesterday, citing a regulatory filing.
The fund sold 4.9 million shares at a price of $77 each, more than four times the price at which Guardant floated in October 2018, though below the $110.30 price at which they peaked last month. SoftBank and its affiliates held almost 27.9 million shares as of the initial public…
